Prelude Therapeutics Incorporated (PRLD) Cash Flow Statement
Where PRLD’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$56.3M
- Capital expenditures
- $67,000 0.6% of revenue
- Free cash flow
- −$56.4M −464.3% margin
- Returned to shareholders
- —
- Change in cash
- $22.0M cash at year-end $38.5M
Drawn to scale: where the cash came from and how it was used. Hover for values.
PRLD operating cash flow, capex and free cash flow
PRLD cash flow trends, 2018–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$13.0M2018 | −$56.3M2025 | — | |
| Capital expenditures | $529,0002018 | $67,0002025 | −25.6%/yr | |
| Free cash flow | −$13.5M2018 | −$56.4M2025 | — | |
| Free cash flow margin | −1,480.7%2024 | −464.3%2025 | +1,016.4 pts | |
| Stock-based compensation | $180,0002018 | $11.9M2025 | +82.0%/yr | |
| Capex / revenue | 10.9%2024 | 0.6%2025 | −10.4 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PRLD cash flow by activity
PRLD net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
PRLD cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||
| Net income | −$99.5M | −$127.2M | −$121.8M | −$115.4M | −$111.7M | −$56.9M | −$27.6M | −$14.7M |
| Depreciation & amortization | $1.7M | $1.8M | $1.2M | $1.3M | $915,000 | $542,000 | $382,000 | $149,000 |
| Stock-based compensation | $11.9M | $21.3M | $25.6M | $25.1M | $20.9M | $5.6M | $846,000 | $180,000 |
| Change in working capital | $28.4M | $4.2M | −$10.5M | $932,000 | $3.6M | $4.6M | $667,000 | $1.4M |
| Other non-cash items | $1.2M | −$3.0M | −$1.5M | $4.3M | $2.7M | $11,000 | $10,000 | $15,000 |
| Cash from operating activities | −$56.3M | −$102.9M | −$107.1M | −$83.7M | −$83.5M | −$46.2M | −$25.7M | −$13.0M |
| Investing activities | ||||||||
| Capital expenditures | −$67,000 | −$764,000 | −$3.5M | −$3.0M | −$2.3M | −$621,000 | −$780,000 | −$529,000 |
| Investments (net) | $53.5M | $90.2M | −$41.0M | $81.7M | −$263.8M | −$621,000 | −$780,000 | −$529,000 |
| Acquisitions & other investing | $0 | $764,000 | $9.9M | $3.0M | $2.3M | $621,000 | $780,000 | $529,000 |
| Cash from investing activities | $53.5M | $90.2M | −$34.6M | $81.7M | −$263.8M | −$621,000 | −$780,000 | −$529,000 |
| Financing activities | ||||||||
| Share repurchases & issuance (net) | — | — | −$17 | — | — | — | — | — |
| Net borrowing (repayment) | −$208,000 | −$395,000 | $0 | — | $0 | −$258,000 | −$124,000 | −$124,000 |
| Shares issued | $24.9M | $0 | $110.8M | $110.7M | $161.4M | $246.4M | $29.8M | $17.9M |
| Other financing | $149,000 | $275,000 | $25.6M | −$109.9M | $3.5M | $88,000 | $5,000 | $124,000 |
| Cash from financing activities | $24.8M | −$120,000 | $136.4M | $815,000 | $164.9M | $246.2M | $29.7M | $17.9M |
| Summary | ||||||||
| Net change in cash | $22.0M | −$12.8M | −$5.3M | −$1.2M | −$182.4M | $199.4M | $3.3M | $4.5M |
| Cash at end of period | $38.5M | $16.5M | $29.3M | $34.6M | $35.9M | $218.3M | $18.9M | $15.6M |
| Free cash flow | −$56.4M | −$103.7M | −$110.6M | −$86.7M | −$85.9M | −$46.8M | −$26.4M | −$13.5M |
| Free cash flow margin | −464.3% | −1,480.7% | — | — | — | — | — | — |
| Capex / revenue | 0.6% | 10.9% | — | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$13.9M | −$10.4M | −$16.5M | −$19.7M | −$31.2M | −$32.1M | −$28.7M | −$32.3M | −$34.7M | −$31.4M | −$33.1M | −$30.6M |
| Depreciation & amortization | $353,000 | $391,000 | $418,000 | $425,000 | $433,000 | $435,000 | $489,000 | $405,000 | $452,000 | $426,000 | $331,000 | $279,000 |
| Stock-based compensation | $2.0M | $2.0M | $1.8M | $2.4M | $3.8M | $3.8M | $3.8M | $5.9M | $6.1M | $5.5M | $5.9M | $6.7M |
| Change in working capital | −$4.1M | −$13.7M | $37.1M | −$2.6M | $739,000 | −$6.9M | $4.3M | −$933,000 | $6.1M | −$5.2M | $3.7M | −$926,000 |
| Other non-cash items | $77,000 | −$1,000 | $196,000 | $334,000 | $170,000 | $463,000 | −$563,000 | −$423,000 | −$935,000 | −$1.1M | −$463,000 | −$1.1M |
| Cash from operating activities | −$15.6M | −$21.7M | $23.1M | −$19.1M | −$26.1M | −$34.2M | −$20.7M | −$27.3M | −$23.1M | −$31.8M | −$23.6M | −$25.7M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | −$20,000 | −$47,000 | −$53,000 | −$63,000 | −$359,000 | −$289,000 | −$1.1M | −$591,000 |
| Investments (net) | −$65.5M | $8.5M | −$60.3M | $40.1M | $11.5M | $62.2M | $22.1M | $10.7M | $26.1M | $31.2M | $7.7M | $15.0M |
| Acquisitions & other investing | $0 | $0 | $0 | $0 | $20,000 | $47,000 | $53,000 | $63,000 | $359,000 | $289,000 | $1.1M | $591,000 |
| Cash from investing activities | −$65.5M | $8.5M | −$60.3M | $40.1M | $11.5M | $62.2M | $22.1M | $10.7M | $26.1M | $31.2M | $7.7M | $15.0M |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | −$5,000 | — | −$5,000 | — | $34 | −$18 | −$16 | −$1 | −$16 |
| Net borrowing (repayment) | $0 | $0 | $0 | $0 | −$53,000 | −$155,000 | −$151,000 | −$148,000 | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $24.9M | $104,000 |
| Other financing | $85.8M | −$314,000 | $24.9M | $0 | $90,000 | $0 | $117,000 | $16,966 | $59,018 | −$13,984 | $301,001 | −$15,984 |
| Cash from financing activities | $85.8M | −$314,000 | $24.9M | −$5,000 | $37,000 | −$160,000 | −$34,000 | −$131,000 | $59,000 | −$14,000 | $25.2M | $88,000 |
| Summary | ||||||||||||
| Net change in cash | $4.7M | −$13.5M | −$12.3M | $21.0M | −$14.5M | $27.8M | $1.3M | −$16.7M | $3.1M | −$584,000 | $9.4M | −$10.6M |
| Cash at end of period | $29.7M | $25.0M | $38.5M | $50.8M | $29.8M | $44.3M | $16.5M | $15.2M | $31.9M | $24.7M | $29.3M | $19.9M |
| Free cash flow | −$15.6M | −$21.7M | $23.1M | −$19.1M | −$26.1M | −$34.3M | −$20.8M | −$27.4M | −$23.4M | −$32.1M | −$24.7M | −$26.3M |
| Free cash flow margin | −273.0% | −473.5% | 409.9% | −294.1% | — | — | −519.9% | −912.0% | — | — | −721.6% | — |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | — | — | 1.3% | 2.1% | — | — | 33.0% | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
PRLD cash generation
In fiscal 2025 (ended December 31, 2025), Prelude Therapeutics generated -$56.3 million of cash from operations and spent $0.1 million on capital expenditures, leaving free cash flow of -$56.4 million, −464.3% of revenue. Cash and equivalents rose by $22.0 million over the year.
Related: PRLD income statement, PRLD balance sheet. See the PRLD stock overview for the latest quote and news.
PRLD cash flow FAQ
What is Prelude Therapeutics's free cash flow?
Prelude Therapeutics's free cash flow was -$56.4 million in fiscal 2025: -$56.3 million of operating cash flow minus $0.1 million of capital expenditures It was -$103.7 million a year earlier..
How much cash does Prelude Therapeutics generate from operations?
Prelude Therapeutics generated -$56.3 million of cash from operating activities in fiscal 2025.
How much does Prelude Therapeutics spend on capital expenditures?
Prelude Therapeutics spent $0.1 million on capital expenditures in fiscal 2025, 0.6% of revenue, compared with $0.8 million the year before.